Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Prevalence, cyto-histo correlation, and molecular and ultrasonographic profile

IF 1.5 4区 医学 Q3 PATHOLOGY Annals of Diagnostic Pathology Pub Date : 2024-10-31 DOI:10.1016/j.anndiagpath.2024.152390
Zhengfan Xu, Alyssa Vitale, Christian Keller, Wamidh Alkhoory, Ziying Zhang, Lisi Yuan
{"title":"Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Prevalence, cyto-histo correlation, and molecular and ultrasonographic profile","authors":"Zhengfan Xu,&nbsp;Alyssa Vitale,&nbsp;Christian Keller,&nbsp;Wamidh Alkhoory,&nbsp;Ziying Zhang,&nbsp;Lisi Yuan","doi":"10.1016/j.anndiagpath.2024.152390","DOIUrl":null,"url":null,"abstract":"<div><div>Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) was introduced in 2017 WHO Classification of Endocrine Tumors. In this study, we aim to characterize the molecular and ultrasonographic profiles of NIFTP and evaluate the performance of fine needle aspiration (FNA) cytology. Consecutive thyroid resections at our institution between 2018 and 2022 were collected; 1282 thyroid resections were identified. NIFTP was diagnosed in 109 cases (prevalence: 8.5 %); 65 (60 %) were the targeted nodules with an average size of 2.5 cm. Among these 65 targeted, 27 had Afirma testing results, 44 had Thyroid Imaging Reporting and Data System (TIRADS) scores, and 53 had FNA results. Of the 27 cases with Afirma reports, 23 were labeled “suspicious”, including 5 with <em>RAS</em>-related mutations (risk of malignancy (ROM) 75 %) and 17 without a reportable genetic alternation (ROM 50 %). 60 % cases with TIRADS scores were classified as TIRADS 4, while 16 % were classified as TIRADS 5. The majority of the 53 FNA cases had a diagnosis of AUS/FLUS (53.7 %) or FN (31.5 %). One additional targeted nodule with a diagnosis of NIFTP had <em>BRAFV600E</em> mutation and was reclassified as papillary thyroid carcinoma. In summary, the majority of the targeted NIFTPs had “suspicious” Afirma testing results (85 %), TIRADS 4 scores (60 %) and either AUS/FLUS (53.7 %) or FN (31.5 %) FNA results. The sensitivity and specificity of cytology for diagnosing NIFTP were 90 % and 57 %, respectively, with a positive predictive value (PPV) of 16 % and negative predictive value of 98 %.</div></div>","PeriodicalId":50768,"journal":{"name":"Annals of Diagnostic Pathology","volume":"73 ","pages":"Article 152390"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1092913424001278","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) was introduced in 2017 WHO Classification of Endocrine Tumors. In this study, we aim to characterize the molecular and ultrasonographic profiles of NIFTP and evaluate the performance of fine needle aspiration (FNA) cytology. Consecutive thyroid resections at our institution between 2018 and 2022 were collected; 1282 thyroid resections were identified. NIFTP was diagnosed in 109 cases (prevalence: 8.5 %); 65 (60 %) were the targeted nodules with an average size of 2.5 cm. Among these 65 targeted, 27 had Afirma testing results, 44 had Thyroid Imaging Reporting and Data System (TIRADS) scores, and 53 had FNA results. Of the 27 cases with Afirma reports, 23 were labeled “suspicious”, including 5 with RAS-related mutations (risk of malignancy (ROM) 75 %) and 17 without a reportable genetic alternation (ROM 50 %). 60 % cases with TIRADS scores were classified as TIRADS 4, while 16 % were classified as TIRADS 5. The majority of the 53 FNA cases had a diagnosis of AUS/FLUS (53.7 %) or FN (31.5 %). One additional targeted nodule with a diagnosis of NIFTP had BRAFV600E mutation and was reclassified as papillary thyroid carcinoma. In summary, the majority of the targeted NIFTPs had “suspicious” Afirma testing results (85 %), TIRADS 4 scores (60 %) and either AUS/FLUS (53.7 %) or FN (31.5 %) FNA results. The sensitivity and specificity of cytology for diagnosing NIFTP were 90 % and 57 %, respectively, with a positive predictive value (PPV) of 16 % and negative predictive value of 98 %.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
具有乳头状核特征的非侵袭性甲状腺滤泡性肿瘤(NIFTP):发病率、细胞组学相关性、分子和超声图谱。
2017年世界卫生组织内分泌肿瘤分类中引入了具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤(NIFTP)。在本研究中,我们旨在描述 NIFTP 的分子和超声特征,并评估细针穿刺(FNA)细胞学的性能。研究收集了我院2018年至2022年间连续进行的甲状腺切除术,共确定了1282例甲状腺切除术。109例确诊为NIFTP(发病率:8.5%);65例(60%)为靶向结节,平均大小为2.5厘米。在这 65 例目标病例中,27 例有 Afirma 检测结果,44 例有甲状腺成像报告和数据系统 (TIRADS) 评分,53 例有 FNA 结果。在 27 例有 Afirma 报告的病例中,23 例被标记为 "可疑",其中 5 例有 RAS 相关突变(恶性肿瘤风险 (ROM) 75%),17 例没有可报告的遗传变异(ROM 50%)。60% 的 TIRADS 评分病例被归类为 TIRADS 4 级,16% 被归类为 TIRADS 5 级。53 个 FNA 病例中,大多数诊断为 AUS/FLUS(53.7%)或 FN(31.5%)。另有一个诊断为 NIFTP 的靶向结节发生了 BRAFV600E 突变,被重新分类为甲状腺乳头状癌。总之,大多数目标 NIFTP 的 Afirma 检测结果为 "可疑"(85%),TIRADS 4 评分为 "可疑"(60%),FNA 结果为 AUS/FLUS(53.7%)或 FN(31.5%)。细胞学诊断 NIFTP 的敏感性和特异性分别为 90% 和 57%,阳性预测值 (PPV) 为 16%,阴性预测值为 98%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.90
自引率
5.00%
发文量
149
审稿时长
26 days
期刊介绍: A peer-reviewed journal devoted to the publication of articles dealing with traditional morphologic studies using standard diagnostic techniques and stressing clinicopathological correlations and scientific observation of relevance to the daily practice of pathology. Special features include pathologic-radiologic correlations and pathologic-cytologic correlations.
期刊最新文献
Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)− breast cancer Editorial Board TRPS1 expression in cytologic specimens of salivary duct carcinoma and other salivary gland tumors PIT-1/SF-1 co-expression in pituitary neuroendocrine tumors (PitNETs) with comprehensive review of the literature: How should we best characterize these neoplasms?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1